Abstracts tagged "spondyloarthritis"

Abstract Number: 1740 • ACR Convergence 2022
Chronic Inflammation in Patients with Rheumatoid Arthritis or Spondyloarthritis Alters Regulatory T Cells Identity
Tessnime Abaab¹, Lyna Mebrek¹, Marie-Christophe Boissier², Luca Semerano³, Jerome Biton¹ and Natacha Bessis¹, ¹INSERM UMR 1125, Sorbonne Paris Nord University, Bobigny, France, ²INSERM UMR 1125, Sorbonne Paris Nord University,Rheumatology Dpt, APHP, GHUPSSD, Avicenne Hosp, Bobigny, France, ³Hopital Avicenne - AP-HP, Sorbonne Paris Nord University, INSERM UMR1125, Bobigny Cedex, France
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are inflammatory autoimmune diseases associated with impaired regulatory T cell (Tregs) function. Tregs identity varies according to their…
Abstract Number: 2259 • ACR Convergence 2022
Complete Resolution of Inflammation on MRI Is Associated with a Better Clinical Response over Time in Patients with Early Axial Spondyloarthritis
valeria Rios-Rodriguez¹, Murat Torgutalp², Christian Althoff³, Hildrun Haibel², Kay-Geert Hermann², Fabian Proft⁴, Mikhail Protopopov⁵, Judith Rademacher⁵, Joachim Sieper² and Denis Poddubnyy⁴, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²Charité - Universitätsmedizin, Berlin, Berlin, Germany, ³Helios Klinikum Emil von Behring, Berlin, Germany, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Magnetic resonance imaging (MRI) of the spine and sacroiliac joints (SIJ) are important tools for the diagnosis of axial SpA and the presence of…
Abstract Number: 0397 • ACR Convergence 2022
Aberrant Global DNA Methylation in Peripheral Blood Cell Subpopulations of Patients with Axial Spondyloarthritis
ERIC TOUSSIROT¹, Sebastien Pasquereau², Charline Vauchy³, Daniel Wendling⁴, Jean Charles Balblanc⁵, caroline Laheurte⁶, Marc Puyraveau⁷ and Georges Herbein², ¹CHU de Besançon, Besançon, France, ²EA EPILAB, Besancon, Besançon, France, ³INSERM CIC-1431, Besancon, Besançon, France, ⁴CHU, University Teaching Hospital, Besançon, France, ⁵Rhumatologie, Hopital Nord Franche Comté, Trevenans, France, ⁶EFS Bourgogne Franche Comté, Biomonotoring Plateform, Besançon, France, ⁷INSERM CIC-1431 CHU, Besançon, France
Background/Purpose: Axial spondyloarthritis (axSpA) corresponds to a group of chronic inflammatory diseases mainly affecting the axial skeleton. TNFa and IL-17A have been identified as key…
Abstract Number: 0425 • ACR Convergence 2022
Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis – Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2)
Sumit Bhatnagar¹, Doerthe Eckert², Sven Stodtmann², In-Ho Song³, Peter Wung³, Wei Liu³ and Mohamed-Eslam Mohamed³, ¹AbbVie, Highland Park, IL, ²AbbVie, Ludwigshafen, Germany, ³AbbVie, Inc., North Chicago, IL
Background/Purpose: The efficacy and safety profile of 15 mg once-daily (QD) upadacitinib (UPA), an oral, reversible, JAK inhibitor has been established in axial spondyloarthritis (axSpA),…
Abstract Number: 1009 • ACR Convergence 2022
Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixekizumab Treated Biological Naïve Patients with Radiographic Axial Spondyloarthritis Achieving Clinically Important Pain at Night Reduction at Week 16: Results from COAST-V Trial
Sofia Ramiro¹, Cédric Lukas², Michael Nissen³, Yves Schymura⁴, Khai Jing Ng⁴, Andrew Bradley⁴, Gabriel Doridot⁴, Soyi Liu-Leage⁵, Antoni Chan⁶ and James Cheng-Chung WEI⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ³Hopitaux Universitaires de Genève, Geneva, Switzerland, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Neuilly sur Seine, France, ⁶Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, ⁷Chung Shan Medical University Hospital, Taichung, Taiwan
Background/Purpose: Ixekizumab (IXE), a monoclonal antibody that selectively targets interleukin IL-17A, has shown efficacy in patients with radiographic axial spondyloarthritis (r-axSpA). Spinal pain, in particular…
Abstract Number: 1154 • ACR Convergence 2022
Axial Spondyloarthritis: Profiling of MiRNAs in Peripheral Blood Mononuclear Cells
Aneta Pekčcová¹, Kristýna Bubová², Monika Gregova³, Šárka Forejtová², Jana Hořínková², Markéta Hušáková², Michal Tomcik⁴, Jindřiška Gatterová², Jiří Vencovský⁵, Karel Pavelka⁶, Ladislav Šenolt⁵ and Jiří Baloun², ¹Institue of Rheumatology, Prague, Prague, Czech Republic, ²Institue of Rheumatology, Prague, Czech Republic, ³Institue of Rheumatology, Prague, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic
Background/Purpose: microRNAs (miRNAs) are small non-coding RNAs, which are essential for correct gene expression. The dysregulation in miRNA expression is accompanied by various diseases and…
Abstract Number: 1491 • ACR Convergence 2022
Clinically Relevant Differences in the Mobility of Patients with Axial Spondyloarthritis Related to Daytime of Performance
David Kiefer¹, Juergen Braun¹, Lucia Schneider¹, Niklas Kolle¹, Uta Kiltz¹, Ioana Andreica², Philipp Sewerin¹, Bjoern Buehring³, susanne herbold¹ and Xenofon Baraliakos⁴, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ³Bergisches Rheuma-Zentrum, Velbert, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with axial spondyloarthritis (axSpA) often experience impairments of spinal mobility and physical function due to inflammation and structural damage. Back pain and morning…
Abstract Number: 1748 • ACR Convergence 2022
Deep Immune Profiling of Cytotoxic T Cells (CTL) from Patients with Ankylosing Spondylitis Revealed a Subset of CTL Co-Expressing PD-1 and TIGIT That Resists Immune Exhaustion
Michael Tang¹, Addison Pacheco², Zoya Qaiyum³, Melissa Lim¹ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Unresolved, chronic inflammation is a key feature of Ankylosing Spondylitis (AS) yet the immunological events perpetuating remain unclear. The strongest genetic association with AS…
Abstract Number: PP07 • ACR Convergence 2022
Remissions and Vigilance
Michael Scepaniak, Cockeysville, MD
Background/Purpose: I've been diagnosed with spondyloarthritis (SpA) for a little more than 7 1/2 years. That diagnosis was preceded by roughly 9 months of significant…
Abstract Number: 0398 • ACR Convergence 2022
Comparison of Spondyloarthritis, Rheumatoid Arthritis and Knee Osteoarthritis Occurring in the Setting of HIV Infection
Benjamin Naovarat¹, John Reveille¹, Mark Hwang², Francis Williams³ and Gloria Salazar⁴, ¹University of Texas McGovern Medical School, Houston, TX, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³Specialists for Health/Wellmed, Shavano Park, TX, ⁴University of Texas Medical School at Houston/McGovern Medical School, Houston, TX
Background/Purpose: Early in the HIV epidemic, autoimmune diseases such as lupus and rheumatoid arthritis (RA) were uncommonly encountered. With the advent of combined antiretroviral therapy…
Abstract Number: 0427 • ACR Convergence 2022
Recapture Rates with Ixekizumab After Withdrawal of Therapy in Patients with Axial Spondyloarthritis: Results at Week 104 from a Randomized Placebo-controlled Withdrawal Study
Robert Landewé¹, Denis Poddubnyy², Proton Rahman³, Rebecca Bolce⁴, Soyi Liu-Leage⁵, Jeffrey Lisse⁶, So Young Park⁷ and Lianne Gensler⁸, ¹Amsterdam University Medical Center, Meerssen, Netherlands, ²Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Memorial University, St. John's, NL, Canada, ⁴Eli Lilly and Company, Cincinnati, OH, ⁵Eli Lilly, Neuilly sur Seine, France, ⁶Eli Lilly and Company, Tucson, AZ, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Here, we describe the final results of the first study of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis re-randomized to either placebo (ixekizumab…
Abstract Number: 1010 • ACR Convergence 2022
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies
Xenofon Baraliakos¹, Pedro Machado², Lars Bauer³, Bengt Hoepken³, Mindy Kim⁴, Thomas Kumke³, Rachel Tham⁵ and Martin Rudwaleit⁶, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²University College London, London, United Kingdom, ³UCB Pharma, Monheim am Rhein, Germany, ⁴UCB Pharma, Smyrna, GA, ⁵UCB Pharma, Slough, UK, Overland Park, KS, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) recently proposed preliminary, more stringent, data-driven definitions for active and structural MRI lesions of the sacroiliac joint…
Abstract Number: 1156 • ACR Convergence 2022
Serum Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Is Increased in Patients with Active Ankylosing Spondylitis (AS) and Persists Despite Anti-TNF Treatment
Charalampos Papagoras¹, Styliani Tsiami², Akrivi Chrysanthopoulou¹, Ioannis Mitroulis¹ and Xenofon Baraliakos³, ¹First Department of Internal Medicine and Laboratory of Molecular Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, ²Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: There is increasing evidence of the pathogenetic role of monocytes and neutrophils in AS, while the neutrophil-to-lymphocyte ratio correlates with disease activity (1). Granulocyte-Monocyte…
Abstract Number: 1492 • ACR Convergence 2022
Treatment with Non-steroidal Anti-inflammatory Drugs Is Associated with Retardation of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: 10-year Results from the GErman SPondyloarthritis Inception Cohort
Murat Torgutalp¹, valeria Rios-Rodriguez², Ani Dilbaryan³, Fabian Proft⁴, Mikhail Protopopov⁵, Maryna Verba⁶, Judith Rademacher⁵, Hildrun Haibel¹, Joachim Sieper¹, Martin Rudwaleit⁷ and Denis Poddubnyy⁴, ¹Charité - Universitätsmedizin, Berlin, Berlin, Germany, ²Charité-Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine, Moscow City Clinical Hospital, Moscow, Russia, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité-Universitätsmedizin Berlin, corporate member of Freie-Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium
Background/Purpose: There are conflicting data regarding the effect of nonsteroidal anti-inflammatory drugs (NSAID) on radiographic spinal progression in axial spondyloarthritis (axSpA). The analysis of the…
Abstract Number: 1771 • ACR Convergence 2022
The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
Yanjie Hao¹, Shereen Oon² and Mandana Nikpour³, ¹The University of Melbourne, Melbourne, Australia, ²The University of Melbourne Department of Medicine at St. Vincent’s Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: The concept of treat-to-target (T2T), a strategy in which treatment is directed to reach and maintain a defined goal such as remission or low…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].